Combination of Irinotecan and a Platinum Agent for Poorly Differentiated Neuroendocrine Carcinomas

Extrapulmonary poorly differentiated neuroendocrine carcinoma (PDNEC) is a rare and highly aggressive neoplasm for which the optimal chemotherapy remains unclear. The objective of this study was to evaluate the outcomes of patients with PDNEC treated with cisplatin and irinotecan (IP) and perform a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramella Munhoz, Rodrigo, de Mendonça Rego, Juliana Florinda, de Celis Ferrari, Anezka Rubim, Ignez Braghiroli, Maria, Mendonça Bariani, Giovanni, Marcelo Hoff, Paulo, Perego Costa, Frederico, Eduardo Flesch Pfiffer, Túlio, Riechelmann, Rachel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804814/
https://www.ncbi.nlm.nih.gov/pubmed/24179651
http://dx.doi.org/10.4081/rt.2013.e39

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804814/
https://www.ncbi.nlm.nih.gov/pubmed/24179651
http://dx.doi.org/10.4081/rt.2013.e39

Ejemplares similares